Venclose Announces Closing of Series B Financing


July 11, 2018—Venclose, Inc., a developer of solutions for the treatment of venous reflux disease, announced the closing of the Series B round of financing that will be used to support new product development as well as expansion of manufacturing capabilities and general corporate purposes.

The company is commercializing its Venclose radiofrequency (RF) ablation system, which is designed to close damaged veins and restore healthy blood flow in patients with venous reflux disease. The Venclose RF system is available in the United States and Europe.

Venclose also announced that Jeffrey G. Carr, MD, has joined the company as Chief Medical Officer.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.